Buyanghuanwu decoction (BYHWD) attenuates hepatic fibrosis in CCl4-induced mice by regulating bile acid metabolism through activating PPARα.

作者：Xia Wei, Zi-Kang Wang, Jiao Wang, Hailin Yang, Fengfeng Zhou, Shenglan Qi, Jianwei Zhang, Xiaoli Shi, Guanglin Xu, Zhengxin Li, Ying Xu, Dingqi Zhang · 发表于：Journal of Ethnopharmacology · 年份：2026 · DOI：10.1016/j.jep.2026.121476 · 被引用次数：1 · 研究领域：Medicine

ETHNOPHARMACOLOGICAL RELEVANCE Buyanghuanwu decoction (BYHWD), a classical Traditional Chinese Medicine (TCM) formula, has been widely used for treating cardiovascular and cerebrovascular diseases in China. Accumulating evidence confirms its efficacy in ameliorating organ fibrosis (e.g., pulmonary, renal and myocardial fibrosis), providing a solid pharmacological basis for exploring its potential therapeutic value in liver fibrosis. AIM OF THE STUDY This study aimed to investigate the anti-liver fibrotic effect of BYHWD in mice and elucidate its underlying molecular mechanisms. MATERIALS AND METHODS Male C57BL/6J mice were intraperitoneally injected with 15% CCl4 for 6 weeks to establish a hepatic fibrosis model, and BYHWD (6.575 g/kg and 26.3 g/kg) or sorafenib were administered by gavage from week 4. Serum biochemical indicators, histopathological staining (H&E, Masson and Sirius red), and hepatic hydroxyproline content were used to assess hepatic injury and fibrosis. Hepatic stellate cell (HSC) activation and TGF-β/Smad signaling pathway, and hepatic inflammation were detected by qPCR, Western blot, immunohistochemistry, immunofluorescence, and arachidonic acid metabolomics assay. Non-targeted metabolomics, quantitative bile acid (BA) profiling, and tandem mass tag (TMT)-labeled quantitative proteomics were employed to explore metabolic and molecular mechanisms. Furthermore, the liver-distributed components of BYHWD were identified using UHPLC-Q-Orbitrap HRMS, followed...